Topical Drug Delivery Market: Growth, Size, Share, and Trends
Topical Drug Delivery Market by Product (Formulation (Semi-solid, Emulsion), Transdermal Patch, Microneedle Patch, Drug-in-adhesive, Matrix Patch), Application (Dermal, Ophthalmic, Nasal, Vaginal, Rectal), End User, Region - Global Forecast to 2030
USD 409.0 BN
MARKET SIZE, 2030
CAGR 8.8%
(2025-2030)
350+
REPORT PAGES
450+
MARKET TABLES
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global topical drug delivery market is projected to reach USD 409.0 billion by 2030, rising from USD 268.4 billion in 2025, with a CAGR of 8.8% during the forecast period. A topical drug delivery system involves applying medication to the body, most often to the skin, to treat various conditions, where the medication either targets the local area or is absorbed into the bloodstream through the dermis. It enables targeted delivery of a drug to specific sites by avoiding fluctuations in drug levels, improving compliance, and making it more suitable for self-medication.
KEY TAKEAWAYS
-
BY PRODUCTThe topical drug delivery market is segmented by product into semi-solid formulations, liquid formulations, solid formulations, transdermal products, and other products. Semi-solid formulations dominate the market due to their convenience and ease of application, limited side effects that improve patient adherence, and ability to topically deliver a wide variety of drug molecules compared to other formulations.
-
BY SITE OF ADMINISTRATIONThe dermal drug delivery segment accounted for the largest share of the global market share. This large share is due to several advantages of dermal drug delivery, including its ease of use, fewer regulatory requirements compared to ophthalmic products, and improved patient compliance for long-term treatments like chronic pain or skin disorders.
-
BY END USERIn 2024, home care settings held the largest market share, driven by their suitability for long-term therapy, increased convenience over inpatient care, and improved treatment adherence. Rising geriatric populations and the growing demand for self-administered drugs further support this segment’s growth.
-
BY REGIONThe Asia Pacific is expected to grow fastest with a CAGR of 10.2%, driven by a high incidence of skin diseases, a rising prevalence of chronic diseases such as diabetes, and an increasing geriatric population. North America accounted for the largest share of the topical drug delivery market, due to the availability of favorable reimbursement options, the implementation of favorable government initiatives, growing affordability & per capita healthcare expenditure, and the presence of a large number of global pharmaceutical giants.
-
COMPETITIVE LANDSCAPEThe major market players have adopted both organic and inorganic strategies, including partnerships and collaborations. For example, in January 2025, Johnson & Johnson received US FDA approval for a New Drug Application (sNDA) for SPRAVATO (esketamine) CIII nasal spray, making this innovative treatment the first and only monotherapy for adults living with major depressive disorder (MDD).
The global topical drug delivery market is projected to reach USD 409.0 billion by 2030, rising from USD 268.4 billion in 2025, with a CAGR of 8.8% during the forecast period. The market is expected to witness significant growth over the coming years, driven by the high prevalence of skin infections, rising pharmaceutical R&D investments, greater focus on patient convenience, increasing cases of burn injuries, and the growing burden of chronic diseases. A key growth opportunity lies in the rising preference for self-administration, especially for chronic skin conditions and pain management, with products such as transdermal patches, medicated creams, and gels enabling at-home treatment and reducing reliance on clinical visits. Additionally, emerging economies like India, Brazil, and Indonesia present untapped potential, supported by rapid urbanization, wider access to OTC dermatology products, and increased healthcare spending by the expanding middle class.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The evolving landscape of the topical drug delivery market highlights key trends and disruptions that are reshaping revenue sources and affecting end-user behavior. As the industry shifts from systems to more technology-driven solutions, new high-growth opportunities are emerging, especially in cloud-based software and AI integration.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Drivers
Impact
Level
Level
-
High incidence of burn injuries
-
Increasing prevalence of skin disorders.
RESTRAINTS
Impact
Level
Level
-
Adverse skin reactions and allergies
-
Drug failure and recalls of TDD systems
OPPORTUNITIES
Impact
Level
Level
-
Growing preference of self-administration and home care
-
High growth potential of emerging economies
CHALLENGES
Impact
Level
Level
-
Technical barriers related to skin irritation and permeability
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: High incidence of burn injuries
Burn management continues to be a major use of topical drug delivery. Antimicrobial formulations such as Fenistil (GSK), Sulfamylon Cream (Mylan), Bactroban (GSK), and Silvadene (Pfizer) are commonly used as first-line treatments. Globally, over 9 million new burn cases are reported each year, with about 180,000 deaths related to burns, mainly in low- and middle-income countries. This increasing disease burden has driven the need for effective topical therapies, including antimicrobial ointments, sustained-release dressings, and advanced smart bandages that promote faster healing and infection prevention. Recent innovations like nanoparticle-infused creams, hydrogel dressings, and microneedle patches are further improving controlled drug release and allowing for real-time wound monitoring.
Restraint: Adverse skin reactions and allergies
While topical formulations like antibacterial, antifungal, anti-inflammatory, and pain-relief products are widely available, some ingredients can cause irritation or allergic reactions. Topical corticosteroids, though frequently prescribed, may provoke hypersensitivity responses, leading to worsening dermatitis or rashes in unrelated areas. Likewise, agents such as bacitracin, benzocaine, and salicylates have been linked to allergic contact dermatitis, especially in patients with pre-existing skin conditions or in elderly populations. In these cases, patients often stop using topical treatments and switch to alternative methods of drug delivery, which presents a challenge for market adoption.
Opportunity: Growing preference of self-administration and home care
The increasing focus on self-care and treatments at home offers significant opportunities for topical drug delivery. The growing elderly population and disruptions in regular outpatient visits during the COVID-19 pandemic have boosted demand for easy-to-use therapies. Transdermal patches, in particular, are becoming more popular because they are painless, convenient, and caregiver-friendly, which reduces reliance on clinical visits and cuts overall healthcare costs. This trend is likely to boost the adoption of self-administered topical and transdermal formulations.
Challenge: Technical barriers related to skin irritation and permeability
The skin’s natural barrier function presents a major hurdle for topical drug delivery. Although it is an ideal site for both local and systemic treatments, drugs with larger molecular weights or poor lipid solubility face limited absorption, which reduces their therapeutic effectiveness. Typically, compounds over 500 Dalton show poor percutaneous absorption, limiting their use for topical applications. These permeability barriers continue to obstruct the adoption of some high-potential drug candidates in topical delivery systems.
Topical Drug Delivery Market: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
FDA sNDA approved SPRAVATO (Esketamine CIII Nasal Spray), as first monotherapy for MDD after ≥2 failed antidepressants | Offers a rapid-acting, non-oral antidepressant option, Patient convenience via nasal spray delivery; avoids systemic first-pass metabolism |
 |
EPSOLAY (benzoyl peroxide cream 5%) is first and only microencapsulated benzoyl peroxide (E-BPO) topical treatment proven to relieve the bumps and blemishes of rosacea | Better tolerability & reduced irritation versus conventional benzoyl peroxide products due to controlled release/microcapsules |
 |
Acquisition of Kedalion Therapeutics and its AcuStream technology: a topical ocular delivery device to deliver front-of-eye medications more precisely | More precise dosing for eye-medications, improved patient comfort; possibly better adherence and efficacy |
 |
Bayer Consumer Health entry into menopause-related topical/gels: CanesMeno Hydration & Comfort Gel (UK) for vaginal atrophy symptoms (dryness, itching etc) | Address unmet needs in women’s health via non-systemic topical formats, which may reduce risks and improve comfort |
 |
Cost-effective generics in dermatology and topical formulations | Affordable access in emerging markets, broad therapeutic portfolio, strong generics play, expanding footprint in dermatology |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The topical drug delivery market ecosystem includes pharmaceutical manufacturers, raw material suppliers, healthcare providers, regulatory authorities, and end users. Manufacturers are central to this ecosystem, focusing on developing topical formulations such as creams, gels, ointments, sprays, and transdermal patches. They rely on suppliers for essential raw materials, including polymers, lipids, excipients, penetration enhancers, nanocarriers, and packaging materials that ensure stability and effective skin absorption. Healthcare providers, including hospitals, clinics, burn centers, ambulatory surgery centers, and home care settings, are major users of topical therapies. They need formulations that deliver accurate dosing, better absorption, minimal side effects, and improved patient compliance, especially for chronic dermatological conditions and wound care. Regulatory agencies such as the FDA (US), EMA (Europe), and CDSCO (India) play a crucial role by establishing strict guidelines for product safety, efficacy, bioavailability, labeling, and pharmacovigilance. These regulations directly influence product development, approval processes, and market strategies. Their increasing preference for painless, non-invasive, self-administered treatments and cosmetically appealing formulations greatly influences innovation and adoption trends within the market.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Topical drug delivery market, By Product:
The market is divided into semi-solid formulations, liquid formulations, solid formulations, transdermal products, and other topical products. In 2024, semi-solid formulations held the largest market share. This dominance is driven by their suitability for APIs with low density, greater stability under atmospheric conditions compared to liquids and solids, and increasing adoption in personalized medicine. Semi-solids also provide unique compositions and improved absorption properties, making them a preferred option across multiple therapeutic areas.
Topical drug delivery market, By Site of Application:
Based on the site of application, the market is classified into dermal, ophthalmic, rectal, vaginal, and nasal drug delivery. In 2024, the dermal drug delivery segment held the largest market share. Its strong position is due to pain-free self-administration, high absorption efficiency, and dosage stability. Additionally, advanced technologies like nanoemulsion-based dermal delivery are increasingly used for conditions such as psoriasis and vitiligo. Nanoemulsion systems are gaining popularity because of benefits like improved stability, mild surfactant requirements, and simple formulation processes.
Topical drug delivery market, By End User
The market is divided into home care settings, hospitals & clinics, burn care centers, ambulatory surgery centers, and other end users. In 2024, the home care settings segment became the largest end-user segment. Growth is driven by the increasing preference for long-term therapy at home, greater convenience compared to inpatient care, and better adherence to prescribed treatments. The rising global geriatric population and growing demand for self-administered therapies further support the expansion of this segment.
REGION
Asia Pacific to be fastest-growing region in global topical drug delivery market during forecast period
The Asia Pacific region is anticipated to experience the highest CAGR worldwide during the forecast period. This growth is mainly driven by the increasing prevalence of skin disorders, burn cases, rising awareness of advanced drug delivery systems, and rapid adoption of innovative pharmaceutical formulations. Countries like China, India, Japan, and Australia are seeing a growing demand for semi-solid, liquid, and transdermal drug formulations as the population increasingly seeks convenient and targeted treatments. Government efforts to strengthen healthcare infrastructure, combined with rising healthcare spending and patient preference for topical over systemic therapies, are further fueling adoption. Moreover, the surge in research and development of new APIs, nanocarrier-based formulations, and patient-friendly delivery technologies is speeding up market penetration—particularly among pharmaceutical companies and dermatology clinics aiming for effective, localized treatments. With robust growth in the dermatology sector, a rising prevalence of chronic skin conditions, and increased investments from global players to serve underserved markets, the Asia Pacific region is set to become a key hub for growth in topical drug delivery solutions.
Topical Drug Delivery Market: COMPANY EVALUATION MATRIX
In the topical drug delivery market matrix, Johnson & Johnson services, Inc. (Star) leads with scale, extensive distribution networks, and a broad portfolio of topical formulations. Hisamitsu Pharmaceutical Co., Inc. (Emerging Leader) is gaining momentum with innovative drug delivery technologies and advanced formulation research. While Johnson & Johnson dominates through global reach and brand recognition, Pfizer’s focus on innovation and new product development positions it for rapid growth toward the leaders’ quadrant.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Johnson & Johnson services, Inc. (US)
- Galderma (Switzerland)
- Bayer AG (Germany)
- Novartis AG (Switzerland)
- AbbVie Inc. (US)
- Glenmark Pharmaceuticals Ltd. (India)
- GSK Plc. (UK)
- Bausch Health Companies Inc. (Canada)
- Hisamitsu Pharmaceuticals Inc. (Japan)
- Cipla (India)
- Viatris Inc. (US)
- Solventum (US)
- Organon group of companies(US)
- Crescita Therapeutics Inc. (Canada)
- Boehringer Ingelheim International GmbH (Germany)
- Pfizer Inc. (US)
- Teva Pharmaceuticals Industries Ltd. (Israel)
- Luye Pharma Group (China)
- Lead Chemical Co., Ltd. (Japan)
- Purdue Pharma L.P. (US)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size Value in 2024 | USD 247.3 BN |
| Revenue Forecast in 2030 | USD 409.0 BN |
| Growth Rate | 8.8% |
| Actual data | 2023–2030 |
| Base year | 2024 |
| Forecast period | 2025–2030 |
| Units considered | Value (USD million/Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered | • By Product: semi-solid formulations, liquid formulations, solid formulations, transdermal products, and other products |
| Regional Scope | North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa |
WHAT IS IN IT FOR YOU: Topical Drug Delivery Market REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Product Analysis | Comparison of top topical drug delivery product: Solid formulations, semi-solid formulation, liquid formulations. Semi-solid formulations dominate due to their advantages like patient convenience, painless drug delivery. | Identify interconnections ; Detect customer migration trends across industries. |
| Company Information | Key players: Johnson & Johnson services, Inc. (US), Galderma (Switzerland), Bayer AG (Germany), Novartis AG (Switzerland), AbbVie Inc. (US) | Insights on revenue shifts towards emerging topical drug technologies. |
| Geographic Analysis | Detailed analysis on Rest of APAC was provided to one of the top players. | Country level demand mapping for new product launches and localization strategy planning. |
RECENT DEVELOPMENTS
- January 2025 : Johnson & Johnson received the US FDA approval of a New Drug Application (sNDA) for SPRAVATO (esketamine) CIII nasal spray, making this innovative treatment the first and only monotherapy for adults living with major depressive disorder (MDD).
- April 2024 : AbbVie broke ground on a new central research building, “LUnA” (LUdwighafens neue Arbeitswelt), investing approximately USD 172 million in its second-largest R&D location worldwide. A state-of-the-art research and laboratory building on the main campus will be home to over 300 researchers and scientists.
- September 2023 : Cosmo Pharmaceuticals N.V. and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd., signed a distribution & license agreement for Winlevi (clascoterone cream 1%) in Europe and South Africa. Under this agreement, Glenmark will receive the exclusive right to commercialize Winlevi in 15 EU countries, South Africa, and the UK.
- September 2023 : Bausch + Lomb Corporation), a subsidiary of Bausch Health Companies Inc. declared the acquisition of XIIDRA (lifitegrast ophthalmic solution) 5%, a nonsteroid eye drop specifically approved to treat the signs and symptoms of dry eye disease focusing on inflammation associated with dry eye, and certain other ophthalmology assets.
- March 2022 : Galderma announced the US launch of TWYNEO (tretinoin and benzoyl peroxide) Cream, 0.1%/3% at the American Academy of Dermatology (AAD), 2022, in Boston, Massachusetts. TWYNEO Cream is the first, and only 0.1% tretinoin and 3% benzoyl peroxide (BPO) 2-in-1 combination proven to rapidly treat moderate to severe facial acne.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TITLE
PAGE NO
1
INTRODUCTION
36
2
RESEARCH METHODOLOGY
41
3
EXECUTIVE SUMMARY
58
4
PREMIUM INSIGHTS
61
5
MARKET OVERVIEW
Explore cutting-edge transdermal innovations amid rising skin disorder treatments and emerging market opportunities.
65
5.1
INTRODUCTION
5.2
MARKET DYNAMICS
5.2.1
DRIVERS
5.2.1.1
INCREASING PREVALENCE OF SKIN DISORDERS
5.2.1.2
HIGH INCIDENCE OF BURN INJURIES
5.2.1.3
GROWING EMPHASIS ON PATIENT CONVENIENCE
5.2.1.4
INCREASING INVESTMENTS IN PHARMACEUTICAL R&D
5.2.1.5
RISING INCIDENCE OF CHRONIC DISEASES
5.2.2
RESTRAINTS
5.2.2.1
ADVERSE SKIN REACTIONS & ALLERGIES
5.2.2.2
DRUG FAILURE & RECALLS OF TDD SYSTEMS
5.2.2.3
HIGH DEVELOPMENT COSTS OF TOPICAL DRUG DELIVERY PRODUCTS
5.2.3
OPPORTUNITIES
5.2.3.1
GROWING PREFERENCE FOR SELF-ADMINISTRATION AND HOME CARE
5.2.3.2
HIGH GROWTH POTENTIAL OF EMERGING ECONOMIES
5.2.4
CHALLENGES
5.2.4.1
TECHNICAL BARRIERS RELATED TO SKIN IRRITATION & PERMEABILITY
5.3
INDUSTRY TRENDS
5.3.1
ADVANCES IN TRANSDERMAL DRUG DELIVERY SYSTEMS
5.3.2
EMERGENCE OF MICRONEEDLE PATCH TECHNOLOGIES
5.4
TECHNOLOGY ANALYSIS
5.4.1
KEY TECHNOLOGIES
5.4.1.1
NANOCARRIER-BASED DELIVERY SYSTEMS
5.4.1.2
MICROEMULSIONS & NANOEMULSION
5.4.1.3
THERMOSENSITIVE & PH-SENSITIVE HYDROGELS & HYDROCOLLOIDS
5.4.2
COMPLEMENTARY TECHNOLOGIES
5.4.2.1
MICRONEEDLE-ENHANCED DELIVERY
5.4.2.2
AI-ASSISTED FORMULATIONS & PREDICTION MODELS
5.4.3
ADJACENT TECHNOLOGIES
5.4.3.1
WEARABLE SENSOR-INTEGRATED TOPICAL PATCHES
5.4.3.2
3D TESTING SKIN MODELS
5.5
PORTER’S FIVE FORCES ANALYSIS
5.5.1
THREAT OF NEW ENTRANTS
5.5.2
THREAT OF SUBSTITUTES
5.5.3
BARGAINING POWER OF SUPPLIERS
5.5.4
BARGAINING POWER OF BUYERS
5.5.5
INTENSITY OF COMPETITIVE RIVALRY
5.6
REGULATORY LANDSCAPE
5.6.1
REGULATORY ANALYSIS
5.6.2
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.7
PATENT ANALYSIS
5.7.1
PATENT PUBLICATION TRENDS FOR TOPICAL DRUG DELIVERY
5.7.2
INSIGHTS: JURISDICTION & TOP APPLICANT ANALYSIS
5.8
TRADE ANALYSIS
5.8.1
TRADE DATA FOR HS CODE 300490
5.8.1.1
IMPORT DATA FOR HS CODE 300490
5.8.1.2
EXPORT DATA FOR HS CODE 300490
5.9
PRICING ANALYSIS
5.9.1
AVERAGE SELLING PRICE TREND, BY PRODUCT, 2022−2024
5.9.2
AVERAGE SELLING PRICE OF OINTMENTS, BY KEY PLAYER, 2024
5.9.3
AVERAGE SELLING PRICE OF GELS, BY KEY PLAYER, 2024
5.9.4
AVERAGE SELLING PRICE, BY REGION
5.9.5
AVERAGE SELLING PRICE OF SEMI-SOLID FORMULATIONS, BY REGION, 2024
5.9.5.1
AVERAGE SELLING PRICE TREND OF OINTMENTS, BY REGION, 2022−2024
5.9.5.2
AVERAGE SELLING PRICE TREND OF CREAMS, BY REGION, 2022−2024
5.9.5.3
AVERAGE SELLING PRICE TREND OF GELS, BY REGION, 2022−2024
5.10
REIMBURSEMENT ANALYSIS
5.11
KEY CONFERENCES & EVENTS, 2025–2026
5.12
KEY STAKEHOLDERS & BUYING CRITERIA
5.12.1
KEY STAKEHOLDERS IN BUYING PROCESS
5.12.2
BUYING CRITERIA
5.13
UNMET NEEDS/END-USER EXPECTATIONS
5.14
IMPACT OF AI ON TOPICAL DRUG DELIVERY MARKET
5.14.1
AI-USE CASES
5.15
PIPELINE ANALYSIS
5.16
ECOSYSTEM MARKET MAP
5.17
VALUE CHAIN ANALYSIS
5.18
INVESTMENT & FUNDING SCENARIO
5.19
TRUMP TARIFF IMPACT ON TOPICAL DRUG DELIVERY MARKET
5.19.1
INTRODUCTION
5.19.2
KEY TARIFF RATES
5.19.3
PRICE IMPACT ANALYSIS
5.19.4
KEY IMPACT ON VARIOUS REGIONS
5.19.5
END-USE INDUSTRY IMPACT
6
TOPICAL DRUG DELIVERY MARKET, BY PRODUCT
Market Size & Growth Rate Forecast Analysis to 2030 in USD Billion and Units | 63 Data Tables
115
6.1
INTRODUCTION
6.2
SEMI-SOLID FORMULATIONS
6.2.1
OINTMENTS
6.2.1.1
WIDE APPLICATIONS IN ANALGESIC INDICATIONS TO DRIVE MARKET
6.2.2
CREAMS
6.2.2.1
HIGH ABSORPTION CAPABILITIES TO BOOST DEMAND
6.2.3
LOTIONS
6.2.3.1
CONVENIENT APPLICATION TO FUEL UPTAKE
6.2.4
GELS
6.2.4.1
ENHANCED PATIENT COMPLIANCE AND AESTHETIC APPEAL TO DRIVE MARKET
6.2.5
PASTES
6.2.5.1
PREVENTION OF SKIN IRRITATION TO FUEL UPTAKE
6.3
LIQUID FORMULATIONS
6.3.1
SUSPENSIONS
6.3.1.1
HIGHER RATE OF BIOAVAILABILITY AND CONTROLLED ONSET OF ACTION TO DRIVE MARKET
6.3.2
EMULSIONS
6.3.2.1
VERSATILE CARRIERS FOR ENHANCED DRUG DELIVERY TO FUEL UPTAKE
6.3.3
SOLUTIONS
6.3.3.1
UNIFORM & RAPID DRUG DELIVERY TO BOOST DEMAND
6.4
SOLID FORMULATIONS
6.4.1
POWDERS
6.4.1.1
INEXPENSIVE MANUFACTURING AND EFFECTIVENESS AGAINST ANTIFUNGAL INFECTIONS TO PROPEL MARKET
6.4.2
SUPPOSITORIES
6.4.2.1
ABILITY TO ENSURE DRUG COMPATIBILITY TO FUEL MARKET
6.4.3
FILM
6.4.3.1
NEXT-GENERATION ADVANCEMENTS TO BOOST DEMAND
6.5
TRANSDERMAL PRODUCTS
6.5.1
TRANSDERMAL PATCHES
6.5.1.1
DRUG-IN-ADHESIVE PATCHES
6.5.1.2
MATRIX PATCHES
6.5.1.3
RESERVOIR MEMBRANE PATCHES
6.5.1.4
MICRONEEDLE PATCHES
6.5.1.5
IONTOPHORESIS PATCHES
6.5.1.6
VAPOR PATCHES
6.5.2
TRANSDERMAL GELS
6.5.2.1
RAPID RELEASE OF DRUGS TO FUEL UPTAKE
6.5.3
TRANSDERMAL SPRAYS
6.5.3.1
TARGETED APPROACH TO BOOST DEMAND
6.6
OTHER PRODUCTS
7
TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION
Market Size & Growth Rate Forecast Analysis to 2030 in USD Billion | 11 Data Tables
172
7.1
INTRODUCTION
7.2
DERMAL DRUG DELIVERY
7.2.1
STANDARD MEDIUM WITH HIGH DRUG ABSORPTION TO PROPEL MARKET
7.3
OPHTHALMIC DRUG DELIVERY
7.3.1
FOCUS ON MICROEMULSION-BASED FORMULATIONS TO BOOST DEMAND
7.4
VAGINAL DRUG DELIVERY
7.4.1
LIMITED INTERVENTION BY MEDICAL PERSONNEL TO DRIVE MARKET
7.5
RECTAL DRUG DELIVERY
7.5.1
COMBINATION OF LOCAL & SYSTEMIC THERAPY OF DRUGS TO FUEL UPTAKE
7.6
NASAL DRUG DELIVERY
7.6.1
QUICK ONSET OF DRUG ACTION & CONVENIENCE TO SUPPORT MARKET UPTAKE
8
TOPICAL DRUG DELIVERY MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2030 in USD Billion | 6 Data Tables
185
8.1
INTRODUCTION
8.2
HOME CARE SETTINGS
8.2.1
HIGH PREFERENCE, AFFORDABILITY, AND CONVENIENCE TO PROPEL MARKET
8.3
HOSPITALS & CLINICS
8.3.1
ADOPTION OF TOPICAL ANAESTHETICS FOR MEDICAL & SURGICAL SUB-SPECIALTIES TO DRIVE MARKET
8.4
AMBULATORY SURGERY CENTERS
8.4.1
UTILIZATION OF ANTIMICROBIAL TOPICAL DRUGS FOR TRAUMA CASES TO BOOST DEMAND
8.5
BURN CARE CENTERS
8.5.1
HIGH INCIDENCE OF BURN INJURIES AND UPTAKE OF OINTMENTS TO SUPPORT MARKET GROWTH
8.6
OTHER END USERS
9
TOPICAL DRUG DELIVERY MARKET, BY REGION
Comprehensive coverage of 8 Regions with country-level deep-dive of 21 Countries | 266 Data Tables.
196
9.1
INTRODUCTION
9.2
NORTH AMERICA
9.2.1
MACROECONOMIC OUTLOOK FOR NORTH AMERICA
9.2.2
US
9.2.2.1
RISING PREVALENCE OF SKIN DISEASES TO DRIVE MARKET
9.2.3
CANADA
9.2.3.1
RISING PREVALENCE OF HYPERTENSION AND FUNDING FOR TOPICAL DRUGS RESEARCH TO DRIVE MARKET GROWTH
9.3
EUROPE
9.3.1
MACROECONOMIC OUTLOOK FOR EUROPE
9.3.2
GERMANY
9.3.2.1
GROWING FOCUS OF R&D FOR PHARMACEUTICAL API DEVELOPMENT TO BOOST DEMAND
9.3.3
UK
9.3.3.1
RISING DEMAND FOR PAINLESS TREATMENT ALTERNATIVES TO FUEL MARKET
9.3.4
FRANCE
9.3.4.1
RISING INCIDENCE OF DIABETES AND SUBSEQUENT INCREASE IN SKIN LESIONS TO DRIVE MARKET
9.3.5
ITALY
9.3.5.1
RISING DEMAND FOR TRANSDERMAL PATCHES TO PROPEL MARKET
9.3.6
SPAIN
9.3.6.1
EXPANDING RESEARCH HUB TO FUEL MARKET
9.3.7
NETHERLANDS
9.3.7.1
PUBLIC AWARENESS INITIATIVES FOR PREVENTIVE CARE TO FUEL UPTAKE
9.3.8
REST OF EUROPE
9.4
ASIA PACIFIC
9.4.1
MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
9.4.2
CHINA
9.4.2.1
RISING CASES OF COMMUNICABLE DISEASES TO DRIVE MARKET
9.4.3
JAPAN
9.4.3.1
INCREASING NUMBER OF PRODUCT APPROVALS TO DRIVE MARKET
9.4.4
INDIA
9.4.4.1
GROWING FOCUS ON ADOPTION OF NON-INVASIVE DRUG DELIVERY METHODS TO DRIVE MARKET
9.4.5
AUSTRALIA
9.4.5.1
INCREASING NUMBER OF SMOKERS TO FUEL UPTAKE
9.4.6
SOUTH KOREA
9.4.6.1
FAVORABLE GOVERNMENT FOCUS ON EXPANDING CLINICAL TRIALS TO BOOST DEMAND
9.4.7
THAILAND
9.4.7.1
REGULATORY REFORMS AND SUPPORTIVE HEALTHCARE INITIATIVES TO SUPPORT MARKET GROWTH
9.4.8
VIETNAM
9.4.8.1
INCREASING INVESTMENTS AND REGULATORY REFORMS TO FUEL UPTAKE
9.4.9
REST OF ASIA PACIFIC
9.5
LATIN AMERICA
9.5.1
MACROECONOMIC OUTLOOK FOR LATIN AMERICA
9.5.2
BRAZIL
9.5.2.1
HIGH PREVALENCE OF DIABETES TO PROPEL MARKET GROWTH
9.5.3
MEXICO
9.5.3.1
INCREASING PREVALENCE OF GLAUCOMA TO DRIVE MARKET
9.5.4
REST OF LATIN AMERICA
9.6
MIDDLE EAST & AFRICA
9.6.1
MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
9.6.2
GCC COUNTRIES
9.6.2.1
KINGDOM OF SAUDI ARABIA (KSA)
9.6.2.2
UNITED ARAB EMIRATES (UAE)
9.6.2.3
OTHER GCC COUNTRIES
9.6.3
REST OF MIDDLE EAST & AFRICA
10
COMPETITIVE LANDSCAPE
Discover which key players dominate the topical drug market with strategic innovation and financial prowess.
323
10.1
OVERVIEW
10.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
10.2.1
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN TOPICAL DRUG DELIVERY MARKET
10.3
REVENUE ANALYSIS, 2020–2024
10.4
MARKET SHARE ANALYSIS
10.4.1
RANKING OF KEY MARKET PLAYERS
10.5
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
10.5.1
STARS
10.5.2
EMERGING LEADERS
10.5.3
PERVASIVE PLAYERS
10.5.4
PARTICIPANTS
10.5.5
COMPANY FOOTPRINT: KEY PLAYERS, 2024
10.5.5.1
COMPANY FOOTPRINT
10.5.5.2
REGION FOOTPRINT
10.5.5.3
PRODUCT FOOTPRINT
10.5.5.4
SITE OF APPLICATION FOOTPRINT
10.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
10.6.1
PROGRESSIVE COMPANIES
10.6.2
RESPONSIVE COMPANIES
10.6.3
DYNAMIC COMPANIES
10.6.4
STARTING BLOCKS
10.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
10.6.5.1
DETAILED LIST OF KEY STARTUPS/SME PLAYERS
10.6.5.2
COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
10.7
BRAND/PRODUCT COMPARISON
10.7.1
TOPICAL DRUG DELIVERY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
10.8
R&D EXPENDITURE OF KEY PLAYERS
10.8.1
R&D EXPENDITURE OF KEY PLAYERS IN TOPICAL DRUG DELIVERY MARKET
10.9
COMPANY VALUATION & FINANCIAL METRICS
10.9.1
FINANCIAL METRICS
10.9.2
COMPANY VALUATION
10.10
COMPETITIVE SCENARIO
10.10.1
PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS
10.10.2
DEALS
10.10.3
EXPANSIONS
10.10.4
OTHER DEVELOPMENTS
11
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
345
11.1
KEY PLAYERS
11.1.1
JOHNSON & JOHNSON SERVICES, INC.
11.1.1.1
BUSINESS OVERVIEW
11.1.1.2
PRODUCTS OFFERED
11.1.1.3
RECENT DEVELOPMENTS
11.1.1.4
MNM VIEW
11.1.2
GALDERMA
11.1.3
BAYER AG
11.1.4
NOVARTIS AG
11.1.5
ABBVIE INC.
11.1.6
GLENMARK PHARMACEUTICALS LIMITED
11.1.7
GSK PLC.
11.1.8
BAUSCH HEALTH COMPANIES INC.
11.1.9
HISAMITSU PHARMACEUTICAL CO., INC.
11.1.10
CIPLA
11.1.11
VIATRIS INC.
11.1.12
ORGANON GROUP OF COMPANIES
11.1.13
PFIZER, INC.
11.1.14
CRESCITA THERAPEUTICS INC.
11.1.15
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
11.1.16
TEVA PHARMACEUTICAL INDUSTRIES LTD.
11.1.17
SOLVENTUM
11.1.18
LUYE PHARMA GROUP
11.1.19
LEAD CHEMICAL CO., LTD.
11.1.20
PURDUE PHARMA L.P.
11.1.21
LAVIPHARM
11.2
OTHER PLAYERS
11.2.1
CMP PHARMA, INC.
11.2.2
ENCORE DERMATOLOGY, INC.
11.2.3
RUSAN PHARMA LTD.
11.2.4
ADHEXPHARMA
12
APPENDIX
426
12.1
DISCUSSION GUIDE
12.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3
RELATED REPORTS
12.4
AUTHOR DETAILS
LIST OF TABLES
TABLE 1
STANDARD CURRENCY CONVERSION RATES (USD)
TABLE 2
TOPICAL DRUG DELIVERY MARKET: RISK ASSESSMENT ANALYSIS
TABLE 3
KEY DEVELOPMENTS FOR TRANSDERMAL DRUG DELIVERY SYSTEMS
TABLE 4
TOPICAL DRUG DELIVERY MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 5
REGULATORY ADHERENCE FOR TOPICAL DRUG DELIVERY PRODUCTS, BY REGION
TABLE 6
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 9
LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 10
MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11
AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12
TOPICAL DRUG DELIVERY MARKET: MAJOR PATENTS
TABLE 13
IMPORT DATA FOR HS CODE 300490, BY COUNTRY, 2021–2024 (USD THOUSANDS)
TABLE 14
EXPORT DATA FOR HS CODE 300490, BY COUNTRY, 2021–2024 (USD THOUSANDS)
TABLE 15
AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT, 2022–2024
TABLE 16
AVERAGE SELLING PRICE TREND OF OINTMENTS, BY REGION, 2022–2024
TABLE 17
AVERAGE SELLING PRICE TREND FOR CREAMS, BY REGION, 2022–2024
TABLE 18
AVERAGE SELLING PRICE TREND OF GELS, BY REGION, 2022–2024
TABLE 19
TOPICAL DRUG DELIVERY MARKET: KEY CONFERENCES & EVENTS, 2025–2026
TABLE 20
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOPICAL DRUG DELIVERY PRODUCTS (%)
TABLE 21
KEY BUYING CRITERIA, BY END USER
TABLE 22
TOPICAL DRUG DELIVERY FORMULATIONS (GLP-1 ANALOGUES) IN CLINICAL PIPELINE (2024)
TABLE 23
TOPICAL DRUG DELIVERY PRODUCTS PROVIDERS: ROLE OF COMPANIES IN ECOSYSTEM
TABLE 24
US-ADJUSTED RECIPROCAL TARIFF RATES
TABLE 25
KEY PRODUCT-RELATED TARIFFS EFFECTIVE FOR TOPICAL DRUG DELIVERY PRODUCTS
TABLE 26
NORTH AMERICA: IMPACT ON CANADA DUE TO US TARIFFS
TABLE 27
ASIA PACIFIC: IMPACT ON CHINA, JAPAN, AND INDIA DUE TO US TARIFFS
TABLE 28
EUROPE: IMPACT ON GERMANY AND UK DUE TO US TARIFFS
TABLE 29
LATIN AMERICA: IMPACT ON MEXICO DUE TO US TARIFFS
TABLE 30
TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
TABLE 31
KEY PLAYERS OFFERING SEMI-SOLID FORMULATIONS
TABLE 32
TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 33
TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 34
KEY PLAYERS OFFERING OINTMENTS
TABLE 35
TOPICAL DRUG DELIVERY MARKET FOR OINTMENTS, BY REGION, 2023–2030 (TEN THOUSAND UNITS)
TABLE 36
TOPICAL DRUG DELIVERY MARKET FOR OINTMENTS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 37
KEY PLAYERS OFFERING CREAMS
TABLE 38
TOPICAL DRUG DELIVERY MARKET FOR CREAMS, BY REGION, 2023–2030 (TEN THOUSAND UNITS)
TABLE 39
TOPICAL DRUG DELIVERY MARKET FOR CREAMS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 40
KEY PLAYERS OFFERING LOTIONS
TABLE 41
TOPICAL DRUG DELIVERY MARKET FOR LOTIONS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 42
KEY PLAYERS OFFERING GELS
TABLE 43
TOPICAL DRUG DELIVERY MARKET FOR GELS, BY REGION, 2023–2030 (TEN THOUSAND UNITS)
TABLE 44
TOPICAL DRUG DELIVERY MARKET FOR GELS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 45
KEY PLAYERS OFFERING PASTES
TABLE 46
TOPICAL DRUG DELIVERY MARKET FOR PASTES, BY REGION, 2023–2030 (TEN THOUSAND UNITS)
TABLE 47
TOPICAL DRUG DELIVERY MARKET FOR PASTES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 48
KEY PLAYERS OFFERING LIQUID FORMULATIONS
TABLE 49
TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 50
TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 51
KEY PLAYERS OFFERING SUSPENSIONS
TABLE 52
TOPICAL DRUG DELIVERY MARKET FOR SUSPENSIONS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 53
KEY PLAYERS OFFERING EMULSIONS
TABLE 54
TOPICAL DRUG DELIVERY MARKET FOR EMULSIONS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 55
KEY PLAYERS OFFERING SOLUTIONS
TABLE 56
TOPICAL DRUG DELIVERY MARKET FOR SOLUTIONS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 57
TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 58
TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 59
KEY PLAYERS OFFERING SOLID FORMULATIONS
TABLE 60
KEY PLAYERS OFFERING POWDERS
TABLE 61
TOPICAL DRUG DELIVERY MARKET FOR POWDERS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 62
KEY PLAYERS OFFERING SUPPOSITORIES
TABLE 63
TOPICAL DRUG DELIVERY MARKET FOR SUPPOSITORIES, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 64
KEY PLAYERS OFFERING FILM
TABLE 65
TOPICAL DRUG DELIVERY MARKET FOR FILM, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 66
TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 67
TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 68
KEY PLAYERS OFFERING TRANSDERMAL PRODUCTS
TABLE 69
KEY PLAYERS OFFERING TRANSDERMAL PATCHES
TABLE 70
TRANSDERMAL PATCHES MARKET, BY TYPE, 2023–2030 (USD BILLION)
TABLE 71
TRANSDERMAL PATCHES MARKET, BY REGION, 2023–2030 (TEN THOUSAND UNITS)
TABLE 72
TRANSDERMAL PATCHES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 73
KEY PLAYERS OFFERING DRUG-IN-ADHESIVE PATCHES
TABLE 74
TRANSDERMAL DRUG-IN-ADHESIVE PATCHES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 75
KEY PLAYERS OFFERING MATRIX PATCHES
TABLE 76
TRANSDERMAL MATRIX PATCHES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 77
KEY PLAYERS OFFERING RESERVOIR MEMBRANE PATCHES
TABLE 78
TRANSDERMAL RESERVOIR MEMBRANE PATCHES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 79
KEY PLAYERS OFFERING MICRONEEDLE PATCHES
TABLE 80
TRANSDERMAL MICRONEEDLE PATCHES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 81
KEY PLAYERS OFFERING IONTOPHORESIS PATCHES
TABLE 82
TRANSDERMAL IONTOPHORESIS PATCHES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 83
KEY PLAYERS OFFERING VAPOR PATCHES
TABLE 84
TRANSDERMAL VAPOR PATCHES MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 85
KEY PLAYERS OFFERING TRANSDERMAL GELS
TABLE 86
TRANSDERMAL GELS MARKET, BY REGION, 2023–2030 (TEN THOUSAND UNITS)
TABLE 87
TRANSDERMAL GELS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 88
KEY PLAYERS OFFERING TRANSDERMAL SPRAYS
TABLE 89
TRANSDERMAL SPRAYS MARKET, BY REGION, 2023–2030 (TEN THOUSAND UNITS)
TABLE 90
TRANSDERMAL SPRAYS MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 91
TOPICAL DRUG DELIVERY MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 92
KEY PLAYERS OFFERING OTHER PRODUCTS
TABLE 93
TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION)
TABLE 94
KEY PLAYERS OFFERING DERMAL DRUG DELIVERY PRODUCTS
TABLE 95
DERMAL DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 96
KEY PLAYERS OFFERING OPHTHALMIC DRUG DELIVERY PRODUCTS
TABLE 97
OPHTHALMIC DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 98
KEY PLAYERS OFFERING VAGINAL DRUG DELIVERY PRODUCTS
TABLE 99
VAGINAL DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 100
KEY PLAYERS OFFERING RECTAL DRUG DELIVERY PRODUCTS
TABLE 101
RECTAL DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 102
KEY PLAYERS OFFERING NASAL DRUG DELIVERY PRODUCTS
TABLE 103
NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 104
TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 105
TOPICAL DRUG DELIVERY MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 106
TOPICAL DRUG DELIVERY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 107
TOPICAL DRUG DELIVERY MARKET FOR AMBULATORY SURGERY CENTERS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 108
TOPICAL DRUG DELIVERY MARKET FOR BURN CARE CENTERS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 109
TOPICAL DRUG DELIVERY MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 110
TOPICAL DRUG DELIVERY MARKET, BY REGION, 2023–2030 (USD BILLION)
TABLE 111
NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 112
NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
TABLE 113
NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 114
NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 115
NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 116
NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 117
NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 118
NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION)
TABLE 119
NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 120
US: KEY MACROINDICATORS
TABLE 121
US: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
TABLE 122
US: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 123
US: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 124
US: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 125
US: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 126
US: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 127
US: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION)
TABLE 128
US: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 129
CANADA: KEY MACROINDICATORS
TABLE 130
CANADA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
TABLE 131
CANADA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 132
CANADA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 133
CANADA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 134
CANADA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 135
CANADA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 136
CANADA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION)
TABLE 137
CANADA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 138
EUROPE: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 139
EUROPE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
TABLE 140
EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 141
EUROPE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 142
EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 143
EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 144
EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 145
EUROPE: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION)
TABLE 146
EUROPE: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 147
GERMANY: KEY MACROINDICATORS
TABLE 148
GERMANY: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
TABLE 149
GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 150
GERMANY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 151
GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 152
GERMANY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 153
GERMANY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 154
GERMANY: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION)
TABLE 155
GERMANY: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 156
UK: KEY MACROINDICATORS
TABLE 157
UK: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
TABLE 158
UK: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 159
UK: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 160
UK: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 161
UK: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 162
UK: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 163
UK: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION)
TABLE 164
UK: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 165
FRANCE: KEY MACROINDICATORS
TABLE 166
FRANCE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
TABLE 167
FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 168
FRANCE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 169
FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 170
FRANCE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 171
FRANCE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 172
FRANCE: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION)
TABLE 173
FRANCE: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 174
ITALY: KEY MACROINDICATORS
TABLE 175
ITALY: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
TABLE 176
ITALY: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 177
ITALY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 178
ITALY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 179
ITALY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 180
ITALY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 181
ITALY: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION)
TABLE 182
ITALY: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 183
SPAIN: KEY MACROINDICATORS
TABLE 184
SPAIN: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
TABLE 185
SPAIN: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 186
SPAIN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 187
SPAIN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 188
SPAIN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 189
SPAIN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 190
SPAIN: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION)
TABLE 191
SPAIN: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 192
NETHERLANDS: KEY MACROINDICATORS
TABLE 193
NETHERLANDS: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
TABLE 194
NETHERLANDS: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 195
NETHERLANDS: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 196
NETHERLANDS: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 197
NETHERLANDS: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 198
NETHERLANDS: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 199
NETHERLANDS: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION)
TABLE 200
NETHERLANDS: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 201
REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
TABLE 202
REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 203
REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 204
REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 205
REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 206
REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 207
REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION)
TABLE 208
REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 209
ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 210
ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
TABLE 211
ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 212
ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 213
ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 214
ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 215
ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 216
ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION)
TABLE 217
ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 218
CHINA: MACROECONOMIC INDICATORS
TABLE 219
CHINA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
TABLE 220
CHINA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 221
CHINA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 222
CHINA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 223
CHINA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 224
CHINA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 225
CHINA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION)
TABLE 226
CHINA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 227
JAPAN: MACROECONOMIC INDICATORS
TABLE 228
JAPAN: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
TABLE 229
JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 230
JAPAN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 231
JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 232
JAPAN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 233
JAPAN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 234
JAPAN: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION)
TABLE 235
JAPAN: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 236
INDIA: MACROECONOMIC INDICATORS
TABLE 237
INDIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
TABLE 238
INDIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 239
INDIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 240
INDIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 241
INDIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 242
INDIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 243
INDIA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION)
TABLE 244
INDIA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 245
AUSTRALIA: KEY MACROINDICATORS
TABLE 246
AUSTRALIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
TABLE 247
AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 248
AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 249
AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 250
AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 251
AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 252
AUSTRALIA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION)
TABLE 253
AUSTRALIA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 254
SOUTH KOREA: MACROECONOMIC INDICATORS
TABLE 255
SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
TABLE 256
SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 257
SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 258
SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 259
SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 260
SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 261
SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION)
TABLE 262
SOUTH KOREA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 263
THAILAND: MACROECONOMIC INDICATORS
TABLE 264
THAILAND: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
TABLE 265
THAILAND: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 266
THAILAND: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 267
THAILAND: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 268
THAILAND: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 269
THAILAND: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 270
THAILAND: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION)
TABLE 271
THAILAND: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 272
VIETNAM: MACROECONOMIC INDICATORS
TABLE 273
VIETAM: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
TABLE 274
VIETAM: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 275
VIETAM: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 276
VIETAM: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 277
VIETAM: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 278
VIETAM: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 279
VIETAM: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION)
TABLE 280
VIETAM: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 281
REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
TABLE 282
REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 283
REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 284
REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 285
REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 286
REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 287
REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION)
TABLE 288
REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 289
LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 290
LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
TABLE 291
LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 292
LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 293
LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 294
LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 295
LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 296
LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION)
TABLE 297
LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 298
BRAZIL: MACROECONOMIC INDICATORS
TABLE 299
BRAZIL: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
TABLE 300
BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 301
BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 302
BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 303
BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 304
BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 305
BRAZIL: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION)
TABLE 306
BRAZIL: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 307
MEXICO: MACROECONOMIC INDICATORS
TABLE 308
MEXICO: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
TABLE 309
MEXICO: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 310
MEXICO: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 311
MEXICO: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 312
MEXICO: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 313
MEXICO: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 314
MEXICO: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION)
TABLE 315
MEXICO: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 316
REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
TABLE 317
REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 318
REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 319
REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 320
REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 321
REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 322
REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION)
TABLE 323
REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 324
MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY REGION, 2023–2030 (USD BILLION)
TABLE 325
MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
TABLE 326
MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 327
MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 328
MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 329
MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 330
MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 331
MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION)
TABLE 332
MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 333
GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2023–2030 (USD BILLION)
TABLE 334
GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
TABLE 335
GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 336
GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 337
GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 338
GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 339
GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 340
GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION)
TABLE 341
GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 342
KINGDOM OF SAUDI ARABIA: KEY MACROINDICATORS
TABLE 343
KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
TABLE 344
KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 345
KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 346
KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 347
KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 348
KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 349
KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION)
TABLE 350
KINGDOM OF SAUDI ARABIA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 351
UNITED ARAB EMIRATES: KEY MACROINDICATORS
TABLE 352
UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
TABLE 353
UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 354
UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 355
UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 356
UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 357
UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 358
UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION)
TABLE 359
UNITED ARAB EMIRATES: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 360
OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
TABLE 361
OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 362
OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 363
OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 364
OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 365
OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 366
OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION)
TABLE 367
OTHER GCC COUNTRIES: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 368
REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2023–2030 (USD BILLION)
TABLE 369
REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 370
REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 371
REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 372
REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2023–2030 (USD BILLION)
TABLE 373
REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY TYPE, 2023–2030 (USD BILLION)
TABLE 374
REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2023–2030 (USD BILLION)
TABLE 375
REST OF MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY END USER, 2023–2030 (USD BILLION)
TABLE 376
OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN TOPICAL DRUG DELIVERY MARKET
TABLE 377
TOPICAL DRUG DELIVERY MARKET: DEGREE OF COMPETITION
TABLE 378
TOPICAL DRUG DELIVERY MARKET: REGION FOOTPRINT
TABLE 379
TOPICAL DRUG DELIVERY MARKET: PRODUCT TYPE FOOTPRINT
TABLE 380
TOPICAL DRUG DELIVERY MARKET: SITE OF APPLICATION FOOTPRINT
TABLE 381
TOPICAL DRUG DELIVERY MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS
TABLE 382
TOPICAL DRUG DELIVERY MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
TABLE 383
TOPICAL DRUG DELIVERY MARKET: PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022−JUNE 2025
TABLE 384
TOPICAL DRUG DELIVERY MARKET: DEALS, JANUARY 2022−JUNE 2025
TABLE 385
TOPICAL DRUG DELIVERY MARKET: EXPANSIONS, JANUARY 2022–JUNE 2025
TABLE 386
TOPICAL DRUG DELIVERY MARKET: OTHERS, JANUARY 2022-JUNE 2025
TABLE 387
JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW
TABLE 388
JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS OFFERED
TABLE 389
JOHNSON & JOHNSON SERVICES, INC.: PRODUCT APPROVALS, JANUARY 2022−JUNE 2025
TABLE 390
JOHNSON & JOHNSON SERVICES, INC.: DEALS, JANUARY 2022−JUNE 2025
TABLE 391
GALDERMA: COMPANY OVERVIEW
TABLE 392
GALDERMA: PRODUCTS OFFERED
TABLE 393
GALDERMA: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–JUNE 2025
TABLE 394
GALDERMA: DEALS, JANUARY 2022–JUNE 2025
TABLE 395
GALDERMA: EXPANSIONS, JANUARY 2022–JUNE 2025
TABLE 396
BAYER AG: COMPANY OVERVIEW
TABLE 397
BAYER AG: PRODUCTS OFFERED
TABLE 398
BAYER AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–JUNE 2025
TABLE 399
BAYER AG: DEALS, JANUARY 2022–JUNE 2025
TABLE 400
NOVARTIS AG: COMPANY OVERVIEW
TABLE 401
NOVARTIS AG: PRODUCTS OFFERED
TABLE 402
NOVARTIS AG: DEALS, JANUARY 2022–JUNE 2025
TABLE 403
NOVARTIS AG: OTHERS, JANUARY 2022−JUNE 2025
TABLE 404
ABBVIE INC.: COMPANY OVERVIEW
TABLE 405
ABBVIE, INC.: PRODUCTS OFFERED
TABLE 406
ABBVIE INC.: PRODUCT LAUNCHES, JANUARY 2022–JUNE 2025
TABLE 407
ABBVIE, INC.: EXPANSIONS, JANUARY 2022–JUNE 2025
TABLE 408
ABBVIE INC.: OTHER DEVELOPMENTS, JANUARY 2022−JUNE 2025
TABLE 409
GLENMARK PHARMACEUTICALS LIMITED: COMPANY OVERVIEW
TABLE 410
GLENMARK PHARMACEUTICALS LIMITED: PRODUCTS OFFERED
TABLE 411
GLENMARK PHARMACEUTICALS LIMITED: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–JUNE 2025
TABLE 412
GLENMARK PHARMACEUTICALS LIMITED: DEALS, JANUARY 2022–JUNE 2025
TABLE 413
GSK PLC.: COMPANY OVERVIEW
TABLE 414
GSK PLC.: PRODUCTS OFFERED
TABLE 415
GSK PLC.: DEALS, JANUARY 2022–JUNE 2025
TABLE 416
GSK PLC.: OTHER DEVELOPMENTS, JANUARY 2022−JUNE 2025
TABLE 417
BAUSCH HEALTH COMPANIES INC.: COMPANY OVERVIEW
TABLE 418
BAUSCH HEALTH COMPANIES, INC.: PRODUCTS OFFERED
TABLE 419
BAUSCH HEALTH COMPANIES INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–JUNE 2025
TABLE 420
BAUSCH HEALTH COMPANIES INC.: DEALS, JANUARY 2022–JUNE 2025
TABLE 421
HISAMITSU PHARMACEUTICAL CO., INC.: COMPANY OVERVIEW
TABLE 422
HISAMITSU PHARMACEUTICAL CO., INC.: PRODUCTS OFFERED
TABLE 423
HISAMITSU PHARMACEUTICAL CO., INC.: PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS, JANUARY 2022–JUNE 2025
TABLE 424
HISAMITSU PHARMACEUTICAL CO., INC.: DEALS, JANUARY 2022–JUNE 2025
TABLE 425
HISAMITSU PHARMACEUTICAL CO., INC.: EXPANSIONS, JANUARY 2022–JUNE 2025
TABLE 426
CIPLA: COMPANY OVERVIEW
TABLE 427
CIPLA: PRODUCTS OFFERED
TABLE 428
CIPLA: DEALS, JANUARY 2022–JUNE 2025
TABLE 429
VIATRIS INC.: COMPANY OVERVIEW
TABLE 430
VIATRIS INC.: PRODUCTS OFFERED
TABLE 431
VIATRIS INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–JUNE 2025
TABLE 432
VIATRIS INC.: DEALS, JANUARY 2022–JUNE 2025
TABLE 433
VIATRIS INC.: OTHER DEVELOPMENTS, JANUARY 2022−JUNE 2025
TABLE 434
ORGANON GROUP OF COMPANIES: COMPANY OVERVIEW
TABLE 435
ORGANON GROUP OF COMPANIES: PRODUCTS OFFERED
TABLE 436
ORGANON GROUP OF COMPANIES: PRODUCT APPROVALS, JANUARY 2022–JUNE 2025
TABLE 437
ORGANON GROUP OF COMPANIES: DEALS, JANUARY 2022–JUNE 2025
TABLE 438
PFIZER INC.: COMPANY OVERVIEW
TABLE 439
PFIZER INC.: PRODUCTS OFFERED
TABLE 440
PFIZER, INC.: PRODUCT APPROVALS, JANUARY 2022−JUNE 2025
TABLE 441
PFIZER, INC.: DEALS, JANUARY 2022−JUNE 2025
TABLE 442
CRESCITA THERAPEUTICS INC.: COMPANY OVERVIEW
TABLE 443
CRESCITA THERAPEUTICS INC.: PRODUCTS OFFERED
TABLE 444
CRESCITA THERAPEUTICS INC.: DEALS, JANUARY 2022–JUNE 2025
TABLE 445
CRESCITA THERAPEUTICS INC.: OTHER DEVELOPMENTS, JANUARY 2022−JUNE 2025
TABLE 446
BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW
TABLE 447
BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS OFFERED
TABLE 448
BOEHRINGER INGELHEIM INTERNATIONAL GMBH: DEALS, JANUARY 2022–JUNE 2025
TABLE 449
BOEHRINGER INGELHEIM INTERNATIONAL GMBH: EXPANSIONS, JANUARY 2022−APRIL 2025
TABLE 450
TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
TABLE 451
TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
TABLE 452
TEVA PHARMACEUTICAL INDUSTRIES LTD.: DEALS, JANUARY 2022−JUNE 2025
TABLE 453
SOLVENTUM: COMPANY OVERVIEW
TABLE 454
SOLVENTUM: PRODUCTS OFFERED
TABLE 455
SOLVENTUM DEALS, JANUARY 2022–JUNE 2025
TABLE 456
LUYE PHARMA GROUP: COMPANY OVERVIEW
TABLE 457
LUYE PHARMA GROUP: PRODUCTS OFFERED
TABLE 458
LUYE PHARMA GROUP: PRODUCT APPROVALS, JANUARY 2022–JUNE 2025
TABLE 459
LUYE PHARMA GROUP: DEALS, JANUARY 2022−JUNE 2025
TABLE 460
LEAD CHEMICAL CO., LTD.: COMPANY OVERVIEW
TABLE 461
PURDUE PHARMA L.P.: COMPANY OVERVIEW
TABLE 462
PURDUE PHARMA L.P.: PRODUCTS OFFERED
TABLE 463
LAVIPHARM: COMPANY OVERVIEW
TABLE 464
LAVIPHARM: PRODUCTS OFFERED
TABLE 465
CMP PHARMA, INC.: COMPANY OVERVIEW
TABLE 466
ENCORE DERMATOLOGY, INC.: COMPANY OVERVIEW
TABLE 467
RUSAN PHARMA LTD.: COMPANY OVERVIEW
TABLE 468
ADHEXPHARMA: COMPANY OVERVIEW
LIST OF FIGURES
FIGURE 1
TOPICAL DRUG DELIVERY MARKET & REGIONAL SEGMENTATION
FIGURE 2
TOPICAL DRUG DELIVERY MARKET: RESEARCH DESIGN
FIGURE 3
PRIMARY SOURCES
FIGURE 4
BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE PARTICIPANTS
FIGURE 5
BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION
FIGURE 6
BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS
FIGURE 7
MARKET SIZE APPROACH: REVENUE SHARE ANALYSIS
FIGURE 8
TOPICAL DRUG DELIVERY MARKET - REVENUE SHARE ANALYSIS ILLUSTRATION: JOHNSON & JOHNSON
FIGURE 9
REVENUE ANALYSIS OF TOP FIVE COMPANIES: TOPICAL DRUG DELIVERY MARKET (2024)
FIGURE 10
PHARMACEUTICAL SALES APPROACH
FIGURE 11
TOP-DOWN APPROACH
FIGURE 12
BOTTOM-UP APPROACH
FIGURE 13
DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN TOPICAL DRUG DELIVERY MARKET (2025–2030): IMPACT ON MARKET GROWTH & CAGR)
FIGURE 14
CAGR PROJECTIONS
FIGURE 15
DATA TRIANGULATION METHODOLOGY
FIGURE 16
TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2025 VS. 2030 (USD BILLION)
FIGURE 17
TOPICAL DRUG DELIVERY MARKET, BY SITE OF APPLICATION, 2025 VS. 2030 (USD BILLION)
FIGURE 18
TOPICAL DRUG DELIVERY MARKET, BY END USER, 2025 VS. 2030 (USD BILLION)
FIGURE 19
GEOGRAPHIC SNAPSHOT OF TOPICAL DRUG DELIVERY MARKET
FIGURE 20
INCREASING PREVALENCE OF SKIN DISORDERS AND RISING INCIDENCE OF BURN INJURIES TO PROPEL MARKET
FIGURE 21
SEMI-SOLID FORMULATIONS SEGMENT IN CHINA ACCOUNTED FOR LARGEST MARKET SHARE IN 2024
FIGURE 22
ASIA PACIFIC REGION TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
FIGURE 23
CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
FIGURE 24
EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD
FIGURE 25
TOPICAL DRUG DELIVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 26
BIOPHARMACEUTICAL R&D SPENDING (2020–2026)
FIGURE 27
TOP PHARMA R&D INVESTMENTS: LEADING COMPANY INVESTMENTS, 2023
FIGURE 28
TOPICAL DRUG DELIVERY MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 29
TOPICAL DRUG DELIVERY MARKET: NUMBER OF GRANTED PATENT APPLICATIONS (JANUARY 2014–JUNE 2025)
FIGURE 30
TOP APPLICANT COUNTRIES/REGIONS FOR TOPICAL DRUG DELIVERY PATENTS (JANUARY 2014–JUNE 2025)
FIGURE 31
AVERAGE SELLING PRICE OF OINTMENTS, BY KEY PLAYER, 2024
FIGURE 32
AVERAGE SELLING PRICE OF GELS, BY KEY PLAYER, 2024
FIGURE 33
AVERAGE SELLING PRICE OF SEMI-SOLID FORMULATIONS, BY REGION, 2024
FIGURE 34
INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOPICAL DRUG DELIVERY PRODUCTS
FIGURE 35
KEY BUYING CRITERIA FOR TOPICAL DRUG DELIVERY PRODUCTS, BY TOP THREE END USERS
FIGURE 36
AI-USE CASES
FIGURE 37
TOPICAL DRUG DELIVERY MARKET: ECOSYSTEM MAP
FIGURE 38
TOPICAL DRUG DELIVERY MARKET: VALUE CHAIN ANALYSIS
FIGURE 39
TOPICAL DRUG DELIVERY MARKET: INVESTMENT & FUNDING SCENARIO, 2020–2024
FIGURE 40
TOPICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 41
NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET SNAPSHOT
FIGURE 42
ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET SNAPSHOT
FIGURE 43
REVENUE ANALYSIS OF KEY PLAYERS IN TOPICAL DRUG DELIVERY MARKET, 2022–2024
FIGURE 44
TOPICAL DRUG DELIVERY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 45
RANKING OF KEY PLAYERS IN TOPICAL DRUG DELIVERY MARKET, 2024
FIGURE 46
TOPICAL DRUG DELIVERY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
FIGURE 47
TOPICAL DRUG DELIVERY MARKET: COMPANY FOOTPRINT
FIGURE 48
TOPICAL DRUG DELIVERY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
FIGURE 49
TOPICAL DRUG DELIVERY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 50
R&D EXPENDITURE OF KEY PLAYERS, 2022–2024
FIGURE 51
EV/EBITDA OF KEY VENDORS
FIGURE 52
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 53
JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2024)
FIGURE 54
GALDERMA: COMPANY SNAPSHOT (2024)
FIGURE 55
BAYER AG: COMPANY SNAPSHOT (2024)
FIGURE 56
NOVARTIS AG: COMPANY SNAPSHOT (2024)
FIGURE 57
ABBVIE, INC.: COMPANY SNAPSHOT (2024)
FIGURE 58
GLENMARK PHARMACEUTICALS LIMITED: COMPANY SNAPSHOT (2024)
FIGURE 59
GSK PLC.: COMPANY SNAPSHOT (2024)
FIGURE 60
BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT (2024)
FIGURE 61
HISAMITSU PHARMACEUTICAL CO., INC.: COMPANY SNAPSHOT (2024)
FIGURE 62
CIPLA: COMPANY SNAPSHOT (2024)
FIGURE 63
VIATRIS INC.: COMPANY SNAPSHOT (2024)
FIGURE 64
ORGANON GROUP OF COMPANIES: COMPANY SNAPSHOT (2024)
FIGURE 65
PFIZER, INC.: COMPANY SNAPSHOT (2024)
FIGURE 66
CRESCITA THERAPEUTICS INC.: COMPANY SNAPSHOT (2024)
FIGURE 67
BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2024)
FIGURE 68
TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2024)
FIGURE 69
SOLVENTUM: COMPANY SNAPSHOT (2024)
FIGURE 70
LUYE PHARMA GROUP: COMPANY SNAPSHOT (2023)
FIGURE 71
COMPANY SNAPSHOT: LAVIPHARM (2024)
Methodology
This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, fundamental market dynamics, and key player strategies.
Secondary Research
This research study used widespread secondary sources; directories, databases such as Dun & Bradstreet, Bloomberg BusinessWeek, and Factiva; white papers; annual reports; and companies’ house documents. Secondary research was used to identify and collect information for this extensive, technical, market-oriented, and commercial study of the global pulse oximeters market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends, to the bottom-most level, geographic markets, and key developments related to the market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.
Primary Research
In the primary research process, various supply and demand sources were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the pulse oximeters market. The primary sources from the demand side include key executives from hospitals, physicians, clinicians, and research institutes.
A breakdown of the primary respondents is provided below:
Note 1: C-level primaries include CEOs, COOs, CTOs, and VPs.
Note 2: Others include sales, marketing, and product managers.
Note 3: Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
All major product manufacturers offering various products were identified at the global/regional level. Revenue mapping was done for the major players and was extrapolated to arrive at the global market value of each type of segment. The topical drug delivery market value was also split into various segments and subsegments at the regional and country levels based on:
- Product mapping of various manufacturers of the topical drug delivery market at the regional and country-level
- Relative adoption pattern of each topical drug delivery market among key end-user segments at the regional and/or country-level
- Detailed primary research to gather qualitative and quantitative information related to segments and subsegments at the regional and/or country level.
- Detailed secondary research to gauge the prevailing market trends at the regional and/or country-level
Global Topical Drug Delivery Market Size: Top-Down & Bottom-Up Approach
Data Triangulation
After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments & subsegments, wherever applicable.
Market Definition
Topical drug delivery products are pharmaceutical formulations designed to be applied directly to the skin or mucous membranes to deliver medication at the site of action or for systemic absorption. These products include creams, gels, ointments, lotions, transdermal patches, sprays, and foams. They are used for treating local conditions, such as skin infections, pain, and inflammation, or for controlled systemic drug release (e.g., hormone therapy).
Stakeholders
- Topical drug delivery product manufacturers & distributors
- Suppliers & distributors of topical drug delivery products
- Hospitals & clinics
- Ambulatory surgery centers
- Home healthcare agencies
- Research & consulting firms
- Contract manufacturing organizations
- Venture capitalists
Report Objectives
- To define, describe, and forecast the topical drug delivery market based on product, site of application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall topical drug delivery market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for market players
- To forecast the size of the topical drug delivery market in regions and their country-wise segments: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players operating in the topical drug delivery market and comprehensively analyze their revenue shares and core competencies
- To track and analyze competitive developments such as product launches & approvals, partnerships, agreements, collaborations, expansions, and acquisitions in the topical drug delivery market
- To benchmark players in the market using the “Competitive Leadership Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product strategy within the topical drug delivery market
Key Questions Addressed by the Report
What are the growth opportunities for the topical drug delivery market?
Growth opportunities include the rising preference for self-administration, increased demand for home care, and high market potential in emerging economies.
What are the segments profiled in the report?
The report is segmented by:
- Product
- Site of Application
- End User
- Region
Who are the leading players in the topical drug delivery market?
Key players include Johnson & Johnson Services, Inc. (US), Galderma (Switzerland), Bayer AG (Germany), Novartis AG (Switzerland), and AbbVie Inc. (US).
What are the factors expected to pose a challenge to the growth of the topical drug delivery market?
Technical barriers, particularly skin irritation and permeability challenges, are expected to hinder growth.
At what CAGR is the topical drug delivery market expected to grow?
The market is projected to grow at a CAGR of 8.8% during the 2025−2030 forecast period.
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Topical Drug Delivery Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free CustomisationGrowth opportunities and latent adjacency in Topical Drug Delivery Market
Before You Go
Expand Beyond Topical Drug Delivery Market
Explore the top 20 industries influencing your market growth
Human and AI Powered Market Intelligence
Find Untapped Markets
Teddy
Jun, 2022
Want more detailed information on how key players are retaining their places in the global Topical Drug Delivery Market. Thank You.
Benjamin
Jun, 2022
Which are the target audience for the global study of Global Topical Drug Delivery Market?.
Joseph
Jun, 2022
Which geography is expected to hold the largest share of the global Topical Drug Delivery Market?.